Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US/EU | 2022

Login to access report north_east
Contact sales account_box

In addition to cognitive symptoms, the pharmaceutical industry is focusing on treating the neuropsychiatric symptoms of Alzheimer’s disease (AD), including agitation. According to Clarivate epidemiology, agitation affects the majority of patients diagnosed with AD and comprises a constellation of disruptive symptoms for patients and their families. With competing brands from Lundbeck / Otsuka, Axsome Therapeutics, Avanir / Otsuka, and Intra-Cellular Therapies (among others) poised to enter the market beginning in 2023 and with blockbuster sales at stake, understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk / benefit profiles of today’s off-label generic options will help identify levers for new product positioning and differentiation in this evolving market.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for agitation in AD?
  • What attributes drive decision-making in agitation in AD, which have limited impact, and which are hidden opportunities?
  • How do current off-label treatments perform on these attributes?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes and price are neurologists willing to make for a hypothetical new drug to treat agitation in AD?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 32 European neurologists fielded in February 2022

Key companies: Otsuka / Lundbeck, Avanir / Otsuka, Axsome Therapeutics, Intra-Cellular Therapies 

Key drugs: Quetiapine, risperidone, olanzapine, aripiprazole, sertraline, lorazepam, gabapentin, Rexulti, AVP-786, AXS-05, ITI-1284 ODT-SL

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
north_east
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
north_east
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…
north_east
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east